The preparation of a book is always a very demanding task that needs to be accomplished within the daily work of every one of the contributors.

We therefore particularly appreciate the effort of all of the contributors and their attempt to keep the deadlines despite their numerous other activities as scientist, physician, spouse, mother and daughter. Thanks to all!

We are also particularly grateful to Stefan Aebi, the only man “allowed” to participate in this project, who had the amiability and the courage to report on his experience as a male breast cancer patient.

Laura Walsh, the editor at Springer, deserves special thanks: her support was continuous, firm and friendly and even during difficult moments she never lost her wonderful balance and her sense of humor.
Index

A
Abbreviated CGA (aCGA), 302
ABC OAS, see Adjuvant Breast Cancer (Ovarian Ablation Suppression)
ABCsG, see Austrian Breast Cancer Study Group
AC, see Doxorubicin, cyclophosphamide
Accelerated partial-breast irradiation (APBI), 258
ACCOG, see Anglo-Celtic Cooperative Group
ACD, see Doxorubicin, cyclophosphamide, docetaxel
ACT, see Doxorubicin, cyclophosphamide, paclitaxel
Activities of daily living (ADL), 301
Acute myeloid leukemia (AML), 130–131
from chemotherapy, 340
cyclophosphamide and, 131
epirubicin and, 131
growth factors and, 131
mitoxantrone and, 131
AD, see Doxorubicin, docetaxel
ADHD, see Attention-deficit/hyperactivity disorder
Adherence, 87, 303, 363
Adjuvant Breast Cancer (Ovarian Ablation Suppression) (ABC OAS), 146, 149
Adjuvant chemotherapy, 121–133
anthracyclines in, 122–124
cardiac toxicity with, 130
cognitive function and, 132
dose intensity with, 125
duration of treatment with, 124
estrogen and, 228–229
hematopoietic stem cell transplantation with, 125
menopause from, 228–229, 293
paclitaxel in, 127–129
pulmonary toxicity with, 131
QOL with, 131–132
sexual function with, 131
taxanes in, 126
toxicities with, 130
Adjuvant endocrine therapy
consensus conferences on, 156
for postmenopausal women, 150–151
for premenopausal women, 140–141
QOL and, 353–363
Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Study (ALTTO), 193, 205, 208–209
Adjuvant! Online, 86
Adjuvant Tamoxifen Longer Against Shorter (ATLAS), 6, 67, 70, 150
Adjuvant Tamoxifen or More (ATOM), 67, 70
Adjuvant Tamoxifen Treatment, Offer More? (ATOM), 6, 150
ADL, see Activities of daily living
Adriamycin, 250
Adverse effects, see Side effects
Advocacy, 451–459
AFC, see Antral follicle count
Age
cognitive function and, 387
costs and, 432–433
CRA and, 369
DFS and, 14
ER and, 14
premenopausal women, 291–297
as prognostic factor, 13
supportive care and, 227
See also Elderly patients;
Postmenopausal women;
Premenopausal women
AGO, see Arbeitsgemeinschaft Gastroenterologische Onkologie
AIs, see Aromatase inhibitors
Akt, 198, 200
lapanitib and, 202
Albumin, pregnancy and, 319
Alcohol, 227
Alkylating agents, 368
ALLRED, 112
Alopecia, from chemotherapy, 361
ALTTO, see Adjuvant Lapanitib and/or Trastuzumab Treatment Optimization Study
Alzheimer’s disease, 405
Amenorrhea, see Chemotherapy-related amenorrhea
American Society for Clinical Oncology (ASCO), 64
on AIs, 307
clinical guidelines by, 74
on fertility preservation, 295–296
follow-up and, 346
on HER2 testing, 191
on SLN biopsy, 257
surveillance guidelines from, 334–338
American Society for Reproductive Medicine, 377
AMH, see Anti-müllerian hormone
Aminoglutethimide, tamoxifen and, 155
AML, see Acute myeloid leukemia
Anemia, cognitive function and, 405
Anastrozole, 19, 150, 151
BMD and, 155, 169–170
DFS with, 306
endometrial cancer and, 306
 exemestane and, 155
gefitinib with, 115
HR with, 306
QOL with, 358
tamoxifen and, 111, 155, 306
TTDR for, 306
vaginal bleeding and, 306
Anglo-Celtic Cooperative Group (ACCOG), 108, 109
Animal studies, on cognitive function, 399–400
Anthracyclines, 7, 121
in adjuvant chemotherapy, 122–124
AML and, 340
cardiac toxicity of, 430
CHF from, 340
in children in utero, 320–321
CMF and, 8, 20
for elderly patients, 309
MS from, 340
for p-53, 24
pCR and, 107–110
PFS with, 263
during pregnancy, 320
recurrence with, 8, 123
tamoxifen and, 262
Taxotere with, 109
Anticytokeratin antibody, 43
Anti-emetics, 404, 430
Anti-HER2 therapies, predictive markers for, 25–26
Anti-müllerian hormone (AMH), 371, 372–373
Antineoplastic agents, pregnancy and, 320
Antral follicle count (AFC), 372
menstrual cycle and, 373
Anxiety, 226, 342, 345
cognitive function and, 403, 408
ANZ BCTG, see Australia and New Zealand Breast Cancer Trials Group
APBI, see Accelerated partial-breast irradiation
APO, see Apolipoprotein E
Apolipoprotein E (APO), 406
Arbeitsgemeinschaft Gastroenterologische Onkologie (AGO), 107, 108, 109
on ETC vs. EC, 248
ARCOSEIN, 284
Arimidex, Tamoxifen, Alone or in Combination (ATAC), 151–152, 429
on AIs, 269, 307
BMD changes with, 173
fracture risk with, 172
on cognitive function, 404
on osteoporosis, 171
on postmenopausal women, 306
on QOL, 355, 357, 360
on side effects, 362
Arimidex-Nolvadex (ARNO), 153
on AIs, 307
ARNO, see Arimidex-Nolvadex
Aromatase inhibitors (AIs), 19, 69, 111, 307, 354
arthralgias with, 155
BMD and, 155
DFS with, 269
duration of, 269
for elderly patients, 304
estrogen and, 270
fracture risk from, 170–173
GNRH-a and, 372
hot flashes with, 155
for male breast cancer, 463
for premenopausal women, 294–295
QOL and, 355
RT and, 259
tamoxifen and, 151–155, 171, 268
timing of, 269–271
See also specific agents
Arthralgias, with AIs, 155
ASCO, see American Society for Clinical Oncology
Ashkenazi Jews, 296, 335
Aspirin, 407
AT, see Doxorubicin, paclitaxel
ATAC, see Arimidex, Tamoxifen, Alone or in Combination
ATLAS, see Adjuvant Tamoxifen Longer Against Shorter
ATOM, see Adjuvant Tamoxifen or More
ATP, 163
Attention-deficit/hyperactivity disorder (ADHD), 407
ATTOM, see Adjuvant Tamoxifen Treatment, Offer More?
Attributable costing, 424
Australia and New Zealand Breast Cancer Trials Group (ANZ BCTG), 270
Austrian Breast Cancer Study Group (ABCSG), 108, 110, 146, 150, 155
on AIs, 307
after tamoxifen, 153
fracture risk of, 172
on tamoxifen, 171
AVCF, see Doxorubicin, vincristine, cyclophosphamide, fluorouracil
Average Wholesale Price (AWP), 427
AWP, see Average Wholesale Price
Axillary lymph nodes, 121
HER2/neu and, 14
as prognostic factor, 14
staging and, 45
AZURE, 164

B
B-25, 125
Basal-like tumors, 16
Baum, Michael, 5
BCIRG, see Breast Cancer International Research Group
bcl-2
ER and, 19
tamoxifen and, 19
BCRP-1, 320
Belgian Adjuvant Study Group, 22
BETH, 205
Bevacizumab, 115
lapatinib and, 205–206
trastuzumab and, 205
BIG, see Breast International Group
Bisphosphonates, 163–175
for AIs fracture risk, 170–173
BMD and, 341
CMF and, 168
osteoporosis and, 166, 173–174
ovarian suppression and, 169–170
during pregnancy, 321–322
safety of, 174
tamoxifen and, 170–171
Blood brain barrier, 405
cognitive function and, 406
Blood vessel invasion, 46–47
BMD, see Bone mineral density
BMT, see Bone marrow transplantation
Body image, 229, 342
Bone marrow metastasis
clostronate and, 164
as prognostic factor, 15–16
Bone marrow transplantation (BMT), 67
Bone metastases, 163
Bone mineral density (BMD) AIs and, 155
anastrozole and, 155, 169–170
bisphosphonates and, 341
chemotherapy and, 167–169
clostronate and, 168–169
CMF and, 169
estrogen and, 166
 exemestane and, 155
goserelin and, 169–170
ibandronate and, 172
letrozole and, 155, 171
with osteoporosis, 166
ovarian suppression and, 169–170
in premenopausal women, 167
tamoxifen and, 341
zoletronic acid and, 169
Bone scans, 333, 336
Brain metastases, 202
BRCA-1, 31, 33, 296, 335, 379
microarray-based expression profiling for, 55
BRCA-2, 33, 296, 335, 379
male breast cancer and, 462
Breast cancer during pregnancy (BCP), see Pregnancy
Breast Cancer International Research Group (BCIRG), 128, 182, 271
on docetaxel, 246
on HER2 testing criteria for cardiac safety, 187
QOL in, 184
on trastuzumab, 184, 271
Breast conserving surgery
mammography and, 335–336
for premenopausal women, 295
Breast International Group (BIG), 25, 150, 151–152, 245
on AIs, 307
fracture risk of, 172
on letrozole, 269, 307
on premenopausal women, 294
Breast International Group Herceptin Adjuvant (HERA), 79–80, 182
on HER2 testing criteria for cardiac safety, 187
on trastuzumab, 185, 271
TTDR in, 184
Breast self-examination (BSE), 335
BSE, see Breast self-examination
Busulfan, 368

C
CA 15-3, 337–338
CA 27.29, 337–338
CAF, see Cyclophosphamide, doxorubicin, fluorouracil
CAF with goserelin (CAF-Z), 147
for premenopausal women, 293
CAF with goserelin and tamoxifen (CAF-ZT), 147
for premenopausal women, 293
CAF-Z, see CAF with goserelin
CAF-ZT, see CAF with goserelin and tamoxifen
Calcium, 174, 341
CALGB, see Cancer and Leukemia Group
Cancer and Leukemia Group (CALGB), 18, 19, 125, 127
on AC dosing, 243
on lapatinib and trastuzumab, 210
Cancer Care Ontario (CCO), 64, 74
CAP, see College of American Pathologists
Capecitabine
AC and, 129
CMF and, 129
for elderly patients, 310
lapatinib and, 201–204
in NX, 107
Carboplatin
in CTC, 249, 393
in TCH, 187
See also Cyclophosphamide, thiotepa, carboplatin
Cardiac toxicity
with adjuvant chemotherapy, 130
with lapatinib, 207
monitoring costs for, 430
with trastuzumab, 130, 185–186, 188
CASA, 266
CCO, see Cancer Care Ontario
CD 31, 46
CD 34, 46
cDNA, 32
CEA, 337–338
CEF, see Cyclophosphamide, epirubicin, fluorouracil
Ceramide, 375
c-ErbB2, 31, 32, 38
CGA, see Comprehensive Geriatric Assessment
Chalmers, T.C., 64
Charlson Index, 432
Chemo-brain, 229, 387
Chemoendocrine therapy, 6–7, 261–263
Chemofog, 387
Chemotherapy, 7–8
alopecia from, 361
AML from, 340
BMD and, 167–169
CHF from, 340
children in utero and, 320–321
CMF and, 264–265
cognitive function and, 229, 387–408
congenital malformations from, 319–320
costs of, 424–429
CRA from, 144, 167, 340
DFS with, 308
dose intensity in, 239–251
duration of, 264–266
for elderly patients, 308–310
fertility and, 361
menstrual cycle and, 368
MS from, 340
OA/ovarian suppression and, 144
osteoarthritis from, 341–342
ovarian function and, 140, 167
ovarian suppression with, 147–148, 308
predictive markers for, 20–26
with pregnancy, 318–320
for premenopausal women, 292
preoperative, 103–116
animal studies on, 399–400  
anxiety and, 403, 408  
blood brain barrier and, 406  
chemotherapy and, 229, 387–408  
CMF and, 389, 394, 401  
DCIS and, 394  
Dd and, 393  
depression and, 403, 408  
distress and, 403  
dose intensity and, 401  
of elderly patients, 301  
docrine therapy and, 403–404  
erthropoietin for, 405  
estrogen and, 403–404  
fatigue and, 402–403  
FEC and, 389, 394  
fluorouracil and, 399–400  
genetics and, 406  
impairment duration in, 402  
interventions for, 407–408  
mechanisms of, 404–406  
menopause and, 405  
MRI for, 400  
MTX and, 399–400  
PET for, 400  
psychosocial variables and, 408  
self-reported, 397–398  
tamoxifen and, 394, 404  
Cold sweats, 360  
College of American Pathologists (CAP), 191  
Comedo tumors, 44  
Communication, 222–224  
in marital support, 442–445  
Comprehensive Geriatric Assessment (CGA), 301–302  
abbreviated, 302  
Computed tomography (CT), 336–337  
Congenital malformations from chemotherapy, 319–320  
from doxorubicin, 319  
from fluorouracil, 319  
Congestive heart failure (CHF) from chemotherapy, 340  
from doxorubicin, 309  
from trastuzumab, 182, 186  
Consensus conferences, 63–75  
on adjuvant endocrine therapy, 156  
Coordination of care, 343–347  
Coping, 225–226  
Core needle biopsies (CNB), 41–42  
FISH and, 42  
IHC and, 42  
tumor size and, 47
Couples, 227
CPG, see Clinical practice guidelines
CRA, see Chemotherapy-related amenorrhoea
Cranial dysostosis, 319
Cribiform tumors, 44
cRR, see Clinical response rate
Cryopreservation, 374
CT, see Computed tomography
CTCs, see Circulating tumour cells
Cut-points, 81
CVAP, see Cyclophosphamide, vincristine, doxorubicin, prednisone
Cyclophosphamide
in ACD, 369
in ACT, 369
AML and, 131, 340
in AVCF, 123
chlorambucil, cyclophosphamide, thiotepa, 249
doxorubicin, cyclophosphamide, tamoxifen, 33
in ETC, 248
fertility and, 368
letrozole with, 113
MS from, 340
tamoxifen and, 7
See also Docetaxel, doxorubicin, cyclophosphamide; Doxorubicin, cyclophosphamide; Epirubicin, cyclophosphamide; Fluorouracil, doxorubicin, cyclophosphamide
Cyclophosphamide, doxorubicin, fluorouracil (CAF), 18, 147
CAF-Z, 147
CAF-ZT, 147, 293
for premenopausal women, 293
with tamoxifen, 22
Cyclophosphamide, epirubicin, fluorouracil (CEF), 22, 108
CMF and, 123–124
costs of, 427
CRA from, 292, 370
Cyclophosphamide, methotrexate, fluorouracil (CMF), 7, 65–66, 105, 107, 115, 121
AC and, 123
anthracyclines and, 8, 20
AVCF and, 123
bisphosphonates and, 168
BMD and, 169
capcitabine and, 129
CEF and, 123–124
chemotherapy and, 263–266
cognitive function and, 389, 394, 401
cost of, 427
CRA from, 292, 340, 361, 369–370
DFS with, 81–82, 85, 141, 144, 149, 264
dose intensity of, 243–244
dose scheduling for, 245
doxorubicin and, 8, 125–126
duration of treatment with, 124
EBCTCG and, 67
EC and, 123
for elderly patients, 309
epirubicin and, 8
for ER positive, 20
goserelin and, 147
HER2 and, 22
HR for, 144
menopause from, 371
OA and, 144
ovarian suppression with, 141, 149, 266
with prednisone, 20
for premenopausal women, 292
recurrence and, 361
with RT, 258, 282, 283
tamoxifen and, 262
Cyclophosphamide, thiopeta, carboplatin (CTC), 249, 393
Cyclophosphamide, vincristine, doxorubicin, prednisone (CVAP), 108, 109
Cytokeratin, 55

D
Danish Breast Cancer Cooperative Group, 19
DCIS, see Ductal carcinomas in situ
Dd, see Dose density
Decision making, 222–224
Deep venous thrombosis, tamoxifen and, 342
Depression, 226, 345
cognitive function and, 403, 408
in elderly patients, 301
DEXA, see Dual-energy X-ray absorptiometry
DFS, see Disease-free survival
Diarrhea, 357, 360
with lapatinib, 204
Dietary supplements, 343
Dilated cardiomyopathy, 130
Disease-free survival (DFS), 81–82
age and, 14
with AIs, 269
with anastrozole, 306
with chemotherapy, 308
with clodronate, 164
with CMF, 81–82, 85, 141, 144, 149, 264
with doxorubicin, 123
in elderly patients, 304
with endocrine therapy, 149
with epirubicin, 309
ER and, 84
Kaplan-Meier method for, 82
with letrozole, 359
NCCTG on, 296
for premenopausal women, 292
STEPP and, 83, 84, 85
with tamoxifen, 141
with taxanes, 246
timing of therapy and, 104
with trastuzumab, 182, 186–187, 271
Distant metastasis-free survival (DMFS), 88
Distress, 226, 342
cognitive function and, 403
screening for, 220–221
Dizziness, 357, 360
DMFS, see Distant metastasis-free survival
DNA, for microarray-based expression profiling, 55
Docetaxel, 33, 105
in ACD, 369
dose intensity of, 243
dose scheduling for, 246–247
doxorubicin and, 128
FEC and, 128
paclitaxel and, 128
vinorelbine and, 189
Docetaxel, carboplatin, trastuzumab (TCH), 187
Docetaxel, doxorubicin, cyclophosphamide (TAC, 107
costs of, 427
FAC and, 128
Donepezil, 407
Dose density (Dd), 70, 107, 245
cognitive function and, 393
during pregnancy, 320
Dose intensity
for AC, 242, 243, 244
with adjuvant chemotherapy, 125
in chemotherapy, 239–251
for CMF, 243–244
cognitive function and, 401
for docetaxel, 243
for doxorubicin, 126
for EC, 244
for FAC, 241, 244
for FEC, 242
for paclitaxel, 243
for taxanes, 243
toxicity and, 242
Doxorubicin, 8
in AD, 108
CHF and, 309
CMF and, 8, 125–126
congenital malformations from, 319
in CVAP, 108
DFS and, 123
docetaxel and, 128
dose intensity of, 126
for elderly patients, 310
fertility and, 368
in PAF, 123
in PAFT, 123
tamoxifen and, 7
See also Cyclophosphamide,
doxorubicin, fluorouracil;
Fluorouracil, doxorubicin,
cyclophosphamide
Doxorubicin, cyclophosphamide (AC), 105,
108, 124
AT and, 129
capcitabine and, 129
CMF and, 123
cost of, 427
CRA and, 340, 369–370
dose intensity for, 242, 243, 244
paclitaxel and, 127, 129
for premenopausal women, 292
trastuzumab and, 181
Doxorubicin, cyclophosphamide, docetaxel
(ACD), CRA from, 369
Doxorubicin, cyclophosphamide, paclitaxel
(ACT), CRA from, 369
Doxorubicin, cyclophosphamide,
tamoxifen, 33
Doxorubicin, docetaxel (AD), 108
Doxorubicin, paclitaxel (AT), 105, 108, 115
AC and, 129
cardiac toxicity of, 430
Doxorubicin, vincristine,
cyclophosphamide, fluorouracil
(AVCF), 123
CMF and, 123
Dual-energy X-ray absorptiometry (DEXA), 173, 174
Ductal carcinomas in situ (DCIS), 106, 295
cognitive function and, 394
mammography for, 44
in premenopausal women, 295
Dyspareunia, tamoxifen and, 341
E

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), 5–6, 63–75, 140
on LHRH, 266
on OA, 143, 144
on OA/Os, 293
on OFS, 266
on premenopausal women, 291–292
on tamoxifen for premenopausal women, 293–294
Early stage breast cancer (EBC), 353
Eastern Cooperative Oncology Group (ECOG), 141, 142
on bevacizumab, 205
on elderly patients, 301
on premenopausal women, 292, 293
on trastuzumab, 205
EBC, see Early stage breast cancer
EBCTCG, see Early Breast Cancer Trialists’ Collaborative Group
EC, see Epirubicin, cyclophosphamide
E-cadherin, 44
ECD, see Extracellular domain
ECHO, see Echocardiogram
Echocardiogram (ECHO), 185
ECOG, see Eastern Cooperative Oncology Group
Economics, 421–436
ECTO, see European Cooperative Trial in Operable Breast Cancer
EEG, see Electroencephalograms
EGF, 200
EGFR, see Epidermal growth factor receptor
EIO, see European Institute of Oncology
Elderly patients, 299–311
AIs for, 304
anthracyclines for, 309
chemotherapy for, 308–310
CMF for, 309
cognitive function of, 301
depression in, 301
DFS in, 304
endocrine therapy for, 306–308
ER in, 303–304
QOL for, 304
RT for, 305–306
surgery for, 304–305
vs. endocrine therapy for, 304
tamoxifen for, 309
See also Postmenopausal women
Electroencephalograms (EEG), 400
ELISA, see Enzyme-linked immunosorbent assay
Embryo cryopreservation, 374, 376–377
Emotional Well Being (EWB), 356, 358
Endocrine therapy, 5–6
cognitive function and, 403–404
costs of, 429–430
DFS with, 149
for elderly patients, 306–308
fertility and, 371–372
HER2/neu and, 9
postoperative treatment, for invasive cancer, 139–157
during pregnancy, 321
preoperative, 103–116, 260–261
side effects of, 362
as supportive care, costs of, 431
vs. surgery, for elderly patients, 304
timing of, 266–272
See also Adjuvant endocrine therapy; specific agents
Endometrial cancer, 141
anastrozole and, 306
tamoxifen and, 151, 341
Enzyme-linked immunosorbent assay (ELISA)
for HER2, 192
for UPA/PAI-1, 16
EORTC, see European Organization for Research and Treatment of Cancer
EORTC QLQ-C30, 355
Epiadriamycin, 250
Epidermal growth factor receptor (EGFR), 115, 129, 198, 284
lapatinib and, 206
Epirubicin, 8, 122–123
AML and, 131
CMF and, 8
DFS with, 309
tamoxifen and, 112
TAU protein and, 25
See also Cyclophosphamide, epirubicin, fluorouracil
Epirubicin, cyclophosphamide (EC), 105, 107
CMF and, 123
dose intensity of, 244
ETC and, 248
Epirubicin, paclitaxel, cyclophosphamide (ETC), EC and, 248
ER, see Estrogen receptors
ErbB, 200
  trastuzumab and, 284
ERP, see Event related potential
Erythropoietin, 247
  for cognitive function, 405
Erythropoietin stimulating factors (ESF),
  during pregnancy, 322
ESF, see Erythropoietin stimulating factors
Estradiol, 270
  GNRH-a and, 371
Estrogen, 139–140
  adjuvant chemotherapy and,
    228–229
  AIs and, 270
  BMD and, 166
  cognitive function and, 403–404
  heart disease and, 342
  metabolism of, 37
Estrogen receptors (ER), 6, 18, 38, 77, 139
  age and, 14
  bcl-2 and, 19
  CMF for, 20
  DFS and, 84
  in elderly patients, 303–304
  HR and, 255
  IHC for, 49, 50–51
  β isotype of, 19
  mortality and, 255
  OA for, 143
  pCR and, 106, 110
  as predictive factor, 17
  pregnancy and, 317
  STEPP and, 83
  tamoxifen for, 20, 67, 139
ETC, see Epirubicin, paclitaxel, cyclophosphamide
European Cooperative Trial in Operable
  Breast Cancer (ECTO), 105, 106, 108
European Institute of Oncology (EIO), 105, 106, 107
European Organization for Research and
  Treatment of Cancer (EORTC),
  64, 74, 108
  on anthracyclines, 264
  on fertility, 296
European Working Group of Breast Cancer
  Screening Pathology, 49
Event related potential (ERP), 400
Evidence Advice Cycle, 74
EWB, see Emotional Well Being
Exemestane, 111, 151
  anastrozole and, 155
  BMD and, 155
  tamoxifen and, 269
Extracellular domain (ECD), 199
F
FAC, see Fluorouracil, doxorubicin, cyclophosphamide
FACT-B + ES, see Functional Assessment of
  Cancer Therapy-Breast + Endocrine Subscale
FASG, see French Adjuvant Study Group
Fatigue, 230, 342
  cognitive function and, 402–403
  off-treatment, 132
FC receptor, 25
FDG-PET, see Fluorodeoxyglucose-
  positron emission tomography
Fear, 453–454
Febrile neutropenia, 129, 430–431
FEC, see Fluorouracil, epirubicin, cyclophosphamide
Fertility, 295–296, 367–381
  chemotherapy and, 361
  cisplatin and, 368
  cyclophosphamide and, 368
  doxorubicin and, 368
  endocrine therapy and, 371–372
  fluorouracil and, 368
  GNRH-a for, 374
  measurement of, 372–373
  MTX and, 368
  OCPs for, 374
Foetal death, from MTX, 319
FinHER, 182, 189
  RFS with, 189
FISH, see Fluorescence in situ hybridization
Fisher, Bernard, 4
Fisher, Edwin, 4
Fluorescence in situ hybridization (FISH),
  18, 183
  CNB and, 42
  costs of, 431–432
  for HER2, 52, 53, 185, 192
  interpretation and scoring for, 54
  Fluorescent quantum dots, 37–38
  IHC and, 38
  Fluorodeoxyglucose-positron emission
    tomography (FDG-PET), 337
Fluorouracil, 8, 262
  AML and, 340
  blood brain barrier and, 405
  cognitive function and, 399–400
Fluorouracil (cont.)
congenital malformations from, 319
fertility and, 368
in mitoxantrone, fluorouracil,
cyclophosphamide, 284
MS from, 340
in PAF, 123
in PAFT, 123
PF, 123
tamoxifen and, 262
See also Cyclophosphamide,
doxorubicin, fluorouracil;
Cyclophosphamide, methotrexate,
fluorouracil
Fluorouracil, doxorubicin,
cyclophosphamide (FAC), 122
CRA from, 369
dose intensity of, 241, 244
OA and tamoxifen and, 149
paclitaxel and, 128
during pregnancy, 318
TAC and, 128
Fluorouracil, epirubicin, cyclophosphamide
(FEC)
cognitive function and, 389, 394
costs of, 427
docetaxel and, 128
dose intensity for, 242
duration of treatment with, 124
lapatinib and, 210
Follicle-stimulating hormone (FSH), 271,
371, 372–373
GNRH-a and, 374–375
IVF and, 377
OCPs and, 373
Follow-up, 331–347
Forest plots, 79
Forward phase arrays (FPA), 34
14-3-3 sigma, 35
FPA, see Forward phase arrays
Fracture risk
from AIs, 170–173
with letrozole, 307
French Adjuvant Study Group (FASG), 125,
146, 148
on FEC, 242
Frozen sections, 43
FSH, see Follicle-stimulating hormone
Fulvestrant, 139
Functional Assessment of Cancer
Therapy-Breast + Endocrine
Subscale (FACT-B + ES), 354,
356–357
Functional status, 300
Functional Well Being (FWB), 356
FWB, see Functional Well Being
G
G1 block, 198
GABG, see Gynecological Adjuvant Breast
Group
GAIN, 164
GBSG, see German Breast Cancer Group
G-CSF, see Granulocyte colony stimulating
factor
Gefitinib, 115
with anastrozole, 115
Gemcitabine, 129
for elderly patients, 310
Gene expression grade index, 15
Gene expression profiles, 114
Genetics, 296–297
cognitive function and, 406
counseling on, 335
testing, before pregnancy, 379
Genomics, 32–33
classifiers in, 85
GEPARDUO, see German Preoperative
Adriamycin and Docetaxel Study
Geriatric Multidimensional Assessment, 302
German Breast Cancer Group
(GBSG), 265
German Preoperative Adriamycin and
Docetaxel Study (GEPARDUO),
107, 108, 109, 110, 112
Ginkgo biloba, 407
Glucocorticosteroids, 404
GnRH, see Gonadotropin-releasing
hormone
GNRH-a, see Gonadotropin-releasing
hormone agonists
Gold, nano-particles with, 38
Gompertzian kinetics, 127, 240
Gonadal function, see Sexual function
Gonadotropin-releasing hormone agonists
(GNRH-a), 371
AIs and, 372
efficacy evidence for, 376
for fertility, 374
FSH and, 374–375
LH and, 374–375
for lymphoma, 375
Gonadotrophins, 270
Gonadotropin-releasing hormone
(GnRH), 112
Goserelin, 150, 361, 375
  BMD and, 169–170
  CMF and, 147
  menopause and, 361
  ovarian function and, 296
  for premenopausal women, 361
  recurrence and, 361
  tamoxifen and, 170
Granisetron, 430
Granulocyte colony stimulating factor (G-CSF), 245, 247
  costs of, 430–431
  during pregnancy, 322
GROCTA, see Gruppo di Ricerca in Oncologia Clinica e Terapie Associate
Growth factors, AML and, 131
Gruppo di Ricerca in Oncologia Clinica e Terapie Associate (GROCTA), 141, 146, 148
Gruppo Universitario Napoletano (GUN), 18
GUN, see Gruppo Universitario Napoletano
GW572016, see Lapatinib
Gynecological Adjuvant Breast Group (GABG), 141, 142
Gynecologic function, see Sexual function

H
H₀, see Null hypothesis
HADS, see Hospital Anxiety and Depression Scale
Halsted, William Steward, 3
Hazard ratio (HR), 78
  with anastrozole, 306
  for CMF, 144
  ER and, 255
  with HER2, 192–193
  for letrozole, 307
  for mortality, 255
  for OA, 144
  with trastuzumab, 192–193
H&E, see Hematoxylin eosin
Headaches, 357, 360
Heart disease, 405
  estrogen and, 342
  myocardial infarction, tamoxifen and, 342
  See also Cardiac toxicity
Helplessness, 225
Hematopoietic stem cell transplantation, with adjuvant chemotherapy, 125
Hematoxylin eosin (H&E), 43, 46
HER2, see Human epidermal growth factor receptor 2
HER2/neu, 23
  axillary nodes and, 14
  endocrine therapy and, 9
  IHC for, 49
  in male breast cancer, 462
  as predictive factor, 17
  pregnancy and, 317
  as prognostic factor, 15
  PST and, 257
  tamoxifen and, 17, 19
  trastuzumab and, 9
  VEGF and, 205
HERA, see Breast International Group Herceptin Adjuvant
HercepTest, 52–53
Herceptin, see Trastuzumab
Heregulin, 200
High Sensitivity Cognitive Screen (HSCS), 394, 402, 407
Histopathology, 41
Hodgkin’s disease, 374
Homocysteine, 405–406
Hopelessness, 225
Hormonal therapy, see Endocrine therapy
Hospital Anxiety and Depression Scale (HADS), 345
Hot flashes, 357, 360
  adherence and, 363
  with AIs, 155
  from tamoxifen, 150, 340–341
HR, see Hazard ratio
HSCS, see High Sensitivity Cognitive Screen
HSP27, 35
Human epidermal growth factor receptor 2 (HER2), 52
  CISH for, 192
  CMF and, 22
  ELISA for, 192
  FISH for, 52, 53, 185, 192
  HR with, 192–193
  IGF-1 and, 202
  IHC for, 20, 52–53, 185
  lapatinib and, 206
  monoclonal antibodies and, 197
  pCR and, 107, 114
  PCR for, 192
  as predictive marker, 20–22
  testing for, 192–193
Human epidermal growth (cont.)
therapies for, predictive markers for, 25–26
TKI for, 129
trastuzumab and, 77, 181–182, 191, 271
chemotherapy for, 114
truncated forms of, 199–200
Human immunodeficiency virus (HIV), 387, 397
Huntington’s disease, 387
Hypertelorism, 319
Hypocalcaemia, 174
Hypofractionated radiotherapy, 285
Hysterectomy, from tamoxifen, 151

I
IADL, see Instrumental activities of daily living
Ibandronate
BMD and, 172
clorendonate and, 164
IBC, see Inflammatory breast cancer
IBCSG, see International Breast Cancer Study Group
IBCSG Trial IX, 81–83
ICD, see International Classification of Diseases
ICE, 164
IES, see Intergroup Exemestane Study
IGF-1, see Insulin-like growth factor 1
IGF-1R, see Insulin-like growth factor 1 receptor
IHC, see Immunohistochemistry
IL-1, see Interleukin-1
IL-6, see Interleukin-6
Immunohistochemistry (IHC), 17, 18, 49, 183
CNB and, 42
for ER, 49, 50–51
fluorescent quantum dots and, 38
for HER2, 20, 52–53, 185
for HER2/neu, 49
interpretation and scoring for, 53–54
for ITC, 46
for micrometastasis, 46
for PR, 49, 50–51
for SLN, 43
for Topo IIα, 24
Inflammatory breast cancer (IBC), lapatinib for, 203, 206
Informational needs, 222–224
Inhibin A, 372

Inhibin B, 371, 372
Insomnia, 229
Instrumental activities of daily living (IADL), 301
Insulin-like growth factor 1 (IGF-1), 25
lapatinib and, 202
Insulin-like growth factor 1 receptor (IGF-1R), HER2 and, 200
INT, see Intergroup
Intelligence quotient (IQ), 387
Intergroup (INT), 145, 146, 147, 148
on taxanes, 247
Intergroup Exemestane Study (IES), 152, 153
on AIs, 307
BMD changes with, 173
fracture risk with, 172
on QOL, 355, 360
Interleukin-1 (IL-1), 406
Interleukin-6 (IL-6), 406
International Breast Cancer Study Group (IBCSG), 123, 142, 143, 145, 150
on AIs, 269
on CMF, 264–265, 269, 369
on CRA, 369
on elderly patients, 305
on premenopausal women, 292, 293, 294
on RT, 282
on tamoxifen and CMF, 262
International Classification of Diseases (ICD), 432
International Collaborative Cancer Group, 309
International Consensus Conference on the Adjuvant Therapy of Primary Breast Cancer, 156
Interstitial pneumonitis, with trastuzumab, 189
Intraductal carcinoma, 44
Invasive cancer
postoperative endocrine therapy for, 139–157
in premenopausal women, 295
In vitro fertilization (IVF), 376–377
FSH and, 377
letrozole and, 377
IORT, 306
IQ, see Intelligence quotient
Irinotecan, lapatinib and, 207
Irritability, 357, 360
Isolated tumor cells (ITC), 45
IHC for, 46
β isotype, of ER, 19
ITA, see Italian Tamoxifen Anastrozole
Italian Breast Cancer Adjuvant Study
Group, see Gruppo di Ricerca in Oncologia Clinica e Terapie Associate
Italian Tamoxifen Anastrozole (ITA), 171
on AIs, 307
fracture risk with, 172
ITC, see Isolated tumor cells
IVF, see In vitro fertilization

J
JIMT-1, 199
John Nick Foundation, 463

K
Kaplan-Meier method, 20, 81
for DFS, 82
STEPP and, 83
Kappa-statistics, 49
Ki67, 19, 106
in premenopausal women, 291
King, Martin Luther, Jr., 452
Kubler-Ross, Elisabeth, 452

L
Lapatinib (Tykerb, GW572016), 25, 129,
197–211
Akt and, 202
bevacizumab and, 205–206
capcitabine and, 201–204
cardiac toxicity with, 207
costs of, 431–432
diarrhea with, 204
EGFR and, 206
FEC and, 210
HER2 and, 206
for IBC, 203, 206
IGF-I and, 202
irinotecan and, 207
letrozole and, 204
LVEF and, 207
MAPK and, 202
for MBC, 203
neoadjuvant therapy with, 209
p95 and, 203
paclitaxel and, 207
PFS with, 204
PI3K and, 202
PTEN and, 115, 206
side effects of, 203
TKI and, 205–206
toxicity of, 206–207
trastuzumab and, 115, 201–202,
204–205, 210
Left ventricular ejection fraction (LVEF),
183, 185
lapatinib and, 207
trastuzumab and, 186
Letrozole, 151, 269
after tamoxifen, 153
BMD and, 155, 171
cost of, 429–430
with cyclophosphamide, 113
DFS with, 359
fracture risk with, 307
HR for, 307
IVF and, 377
lapatinib and, 204
MENQOL with, 359
recurrence with, 152
tamoxifen and, 111
Leukemia
murine cell line, 239–240
See also Acute myeloid leukemia
Leuprolrelin acetate, 144
LH, see Luteinizing hormone
LHRH, see Luteinizing hormone releasing
hormone
Libido, 357, 360
tamoxifen and, 341
L-PAM, see Single agent phenylalanine
mustard
LumA tumors, 16
LumB tumors, 16
Luteinizing hormone (LH), 271, 371, 372
GNRH-a and, 374–375
OCPs and, 373
Luteinizing hormone releasing hormone
(LHRH), 143, 149, 157, 361
OFS and, 266–267
tamoxifen and, 170
triptorelin and, 148
LVEF, see Left ventricular ejection fraction
Lymphedema, 339
weight gain and, 339
Lymph nodes, 4
axillary, 121
HER2/neu and, 14
as prognostic factor, 14
staging and, 45
in premenopausal women, 291
recurrence and, 141
Lymph nodes (cont.)
SLN
  biopsy of, 257, 339
  dissection of, 45–46
  IHC for, 43
Lymphoma, GNRH-a for, 375
Lymph vessel invasion, 46–47

M
MA17, 171
  on AIs, 307
  BMD changes with, 173
  on letrozole, 359
  on QOL, 355, 359
Magnetic resonance imaging (MRI), 36, 337
  for cognitive function, 400
  nano-particles and, 38
MALDI-TOF, see Matrix-assisted laser desorption and ionization with time of flight spectrometry
Male breast cancer, 461–464
  AIs for, 463
  BRCA-2 and, 462
  HER2/neu in, 462
  QOL and, 463
Mammaglobin/liophilinB complex, 35
Mammography, 333, 344
  breast conserving surgery and, 335–336
  for ductal carcinomas in situ, 44
  tumor grade and, 45
MAP, see Mitogen-activated protein
MAPK, see Mitogen-activated protein kinase
Marital support, 441–448
  communication in, 442–445
  mutuality in, 445–446
Mass spectrometry, 37
Mastectomy, 295
  RT and, 282
Matrix-assisted laser desorption and ionization with time of flight spectrometry (MALDI-TOF), 34
MBC, see Metastatic breast cancer
M.D. Anderson group, 25, 106, 109–110, 122, 128
  on pregnancy, 317
MDMs, see Multidisciplinary Meetings
MDTs, see Multidisciplinary teams
Medicare, AWP of, 427
Medroxyprogesterone acetate, 262
Methotrexate (MTX), 8, 250
  AML and, 340
  blood brain barrier and, 405
  cognitive function and, 399–400
  fertility and, 368
  fetal death from, 319
  MS from, 340
  See also Cyclophosphamide, methotrexate, fluorouracil
Methylphenidate, 407
Microarray-based expression profiling, 16, 32–33, 55–57
  for BRCA-1, 55
  DNA for, 55
  RNA for, 55
Microarray In Node negative Disease may Avoid ChemoTherapy (MINDACT), 48, 77, 85–88
Microcosting, 424
Micrognathia, 319
Micrometastasis, IHC for, 46
Microtubule-associated parameters (MTAP), 25
MIG-6, see Mitogen-inducible gene 6 protein
MINDACT, see Microarray In Node negative Disease may Avoid ChemoTherapy
Mini Mental State Examination, 397
Mitogen-activated protein (MAP), 198
Mitogen-activated protein kinase (MAPK), 260
lapatinib and, 202
Mitogen-inducible gene 6 protein (MIG-6), 200
Mitoxantrone, AML and, 131
Mitoxantrone, fluorouracil, cyclophosphamide, 284
Monoclonal antibodies, 7
HER2 and, 197
See also specific antibodies
Mood swings, 357, 360
Mortality, 66, 255, 300, 334
ER and, 255
fetal death, 319
HR for, 255
MRI, see Magnetic resonance imaging
MS, see Myelodysplastic syndrome
MTAP, see Microtubule-associated parameters
MTX, see Methotrexate
MUC4, 199
MUGA, see Multigated acquisition
Multidisciplinary Meetings (MDMs), 94
Multidisciplinary teams (MDTs), 93–99
Multigated acquisition (MUGA), 185
Multiple sclerosis, 387
Multivariate Cox analysis, 16, 20, 114
Murine leukemia cell line, 239–240
Mutuality, in marital support, 445–446
Myelodysplastic syndrome (MS), 130
from chemotherapy, 340
Myocardial infarction, tamoxifen and, 342

N
Nano-particles, 37–38
with gold, 38
MRI and, 38
Narcolepsy, 407
National Cancer Institute Common Toxicity Criteria (NCI-CTC), 186, 187
National Cancer Institute of Canada, 123–124
on tamoxifen and CMF, 262
National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG), 153
National Cancer Institute’s Breast Intergroup INT C9741 trial, 8
National Comprehensive Cancer Network (NCCN), 64, 74
on G-CSF, 430
on trastuzumab, 190
National Epirubicin Adjuvant Trial, 8
National Institutes of Health (NIH US), 64, 72
National Surgical Adjuvant Breast and Bowel Project (NSABP), 4, 19–20, 22, 86, 105, 109, 121, 124, 125, 127, 141, 142
on anthracyclines, 309
on clodronate, 164
on docetaxel, 246
on dose intensity, 242
on HER2 testing, 192
on HER2 testing criteria for cardiac safety, 187
on lapatinib, 210
on premenopausal women, 292
on RT and tamoxifen, 284
on SLN biopsy, 257
on tamoxifen, 342
for premenopausal women, 293–294
on trastuzumab, 182, 184, 271
TTDR in, 184
NATO, see Nolvadex Adjuvant Trial Organization
Nausea, 357, 360, 430
NCCN, see National Comprehensive Cancer Network
NCCTG, see North Central Cancer Treatment Group
NCIC-CTG, see National Cancer Institute of Canada Clinical Trials Group
NCI-CTC, see National Cancer Institute Common Toxicity Criteria
NeoAdjuvant Herceptin (NOAH), 115
neo-Adjuvant Lapatinib Trastuzumab Trial Optimization (neo-ALTTO), 115, 209–210
Neoadjuvant therapy, with lapatinib, 209
neo-ALTTO, see neo-Adjuvant Lapatinib Trastuzumab Trial Optimization
Neurotransmitters, 405
New York Heart Association (NYHA), 186, 187
Night sweats, 357, 360
from tamoxifen, 340–341
NIH US, see National Institutes of Health
NOAH, see NeoAdjuvant Herceptin
Nolvadex Adjuvant Trial Organization (NATO), 5, 141, 142
Normal Breast-like tumors, 16
North Central Cancer Treatment Group (NCCTG), 182
on DFS, 296
on HER2 testing, 187, 192
on trastuzumab, 184, 271
with RT, 284
Norton Simon hypothesis, 240
NSABP, see National Surgical Adjuvant Breast and Bowel Project
Nuclear pleomorphism, 48
Null hypothesis (H0), 78
Nutritional supplements, 343
NX, see Vinorelbine, capecitabine
NYHA, see New York Heart Association

O
OA, see Ovarian ablation
OA/OS, see Ovarian ablation/ovarian suppression
OCPs, see Oral contraceptives
Off-treatment fatigue, 132
OFS, see Ovarian function ablation/suppression
Oligomenorrhea, 131
OncoType DX, 86, 113, 149, 150
Ondansetron, 322, 430
Oocyte cryopreservation, 374, 377–378
Oophorectomy, tamoxifen and, 294
Opioids, 404
OPTION, 375
Oral contraceptives (OCPs), 373
for fertility, 374
OS, see Ovarian suppression; Overall survival
Osteonecrosis, 174
Osteoporosis, 171
bisphosphonates and, 166, 173–174
BMD with, 166
from chemotherapy, 341–342
tamoxifen and, 170
zoledronic acid and, 170, 173
Ovarian ablation (OA)
CMF and, 144
EBCTCG and, 67
for ER positive, 143
HR for, 144
for premenopausal women, 140–141, 292–293
tamoxifen and, 143, 148–149
Ovarian ablation/ovarian suppression (OA/OS), 143–144
chemotherapy and, 144
EBCTCG on, 293
Ovarian function, 139–140
chemotherapy and, 140, 167
damage mechanisms with, 368–369
goserelin and, 296
Ovarian function ablation/suppression (OFS), 266–267
Ovarian suppression (OS), 367, 368
bisphosphonates and, 169–170
BMD and, 169–170
with chemotherapy, 147–148, 308
with Clodronate, 164
with CMF, 141, 149, 264
for premenopausal women, 292–293
with tamoxifen, 141
timing of therapy and, 104
with trastuzumab, 182, 188
Ovarian tissue cryopreservation, 374, 378–379
Overall survival (OS), 18, 142, 250
Oxford Overview Group, 64–65, 122

P
p27, 198
p38, 260
p-53, 19
anthracyclines for, 24
taxanes for, 24
p95, 193, 199, 209
lapatinib and, 202
tristuzumab and, 202
P450(CYP)3A4, 207
Paclitaxel
in AT, 105, 108, 115
AC and, 127, 129
in ACT, CRA from, 369
in adjuvant chemotherapy, 127–129
cardiotoxicity of, 430
cardiotoxicity with, 130, 430
docetaxel and, 128
dose intensity of, 243
in ETC, 248
FAC and, 128
lapatinib and, 207
TAU protein and, 25
PACS, 128
PAF, see Melphalan, fluorouracil, doxorubicin
PAFT, see Melphalan, fluorouracil, doxorubicin, tamoxifen
Papillary type tumors, 44
Parkinson’s disease, 387
Partners, 227
Pathological response (pCR), 105–107
  anthracyclines and, 107–110
  ER and, 106, 110
  HER2 and, 107, 114
  PgR and, 106
  PST and, 257
Patient reported outcomes (PROs), 358
Pazopanib, 205–206
P-cadherin, 55
PCOs, see Provisional Clinical Opinions
PCP, see Primary care physician
PCR, see Polymerase chain reaction
pCR, see Pathological response
PEBC, see Practice in Evidence Based Care
Peritumoral vascular invasion, as prognostic factor, 15
Personality disorders, 226–227
PET, see Positron emission tomography
PET/CT, see Positron emission tomography computed tomography
Peto, Richard, 65
PF, see Melphalan, fluorouracil
PFS, see Progression free survival
P-glycoprotein (PGP), 320
PGP, see P-glycoprotein
PgR, see Progesterone receptors
PH, see Proportional hazards
Phosphatidylinositol-3-OH (PI3K), 25, 198
  lapatinib and, 202
Physical Well Being (PWB), 356
PI3K, see Phosphatidylinositol-3-OH
Plasma phosphatase and tensin (PTEN), 25, 198
  lapatinib and, 115, 206
  trastuzumab and, 193, 200
Politics, 457–458
Polymerase chain reaction (PCR), 18
  anthracyclines and, 107–110
  for HER2, 192
  taxanes and, 107–110
Positive yielding, 226
Positron emission tomography (PET), for cognitive function, 400
Positron emission tomography computed tomography (PET/CT), 36
Postmenopausal women
  adjuvant endocrine therapy for, 140–141
  AIs for, 294–295
  BMD in, 167
  breast conserving surgery for, 295
  CAF for, 293
  CAF-Z for, 293
  CAF-ZT for, 293
  chemotherapy for, 292
  CMF for, 292
  DCIS in, 295
  ECOG on, 293
  goserelin for, 361
  invasive cancer in, 295
  OA in, 140–141
  oophorectomy with tamoxifen for, 294
  psychosocial variables in, 297
  QOL in, 361–362
  tamoxifen for, 141, 293–294
Pre-morbid psychiatric disorder, 226
Preoperative systemic therapy, see Primary systemic therapy
Postoperative Radiotherapy In Minimum-risk Elderly (PRIME), 306
Post traumatic stress disorder, 226
PR, see Progesterone receptors
Practice in Evidence Based Care (PEBC), 64, 74
Prednisone
  CMF with, 20
  in CVAP, 108
Pregnancy, 295–296, 317–325
  albumin and, 319
  algorithm for, 323–324
  anthracyclines during, 320
  antineoplastic agents and, 320
  bisphosphonates during, 321–322
  chemotherapy with, 318–320
  CRA and, 372
  Dd during, 320
  endocrine therapy during, 321
  ER and, 317
  FAC during, 321
  genetic testing before, 379
  HER2/neu and, 317
  PR and, 317
  recurrence and, 379
  renal blood flow during, 319
  safety of, 379–380
  supportive care during, 322
  tamoxifen during, 321
  taxanes during, 320
  total body water during, 319
  trastuzumab during, 321
Premenopausal women, 291–297
  AC for, 292
  adjuvant endocrine therapy for, 140–141
  AIs for, 294–295
  BMD in, 167
  breast conserving surgery for, 295
  CAF for, 293
  CAF-Z for, 293
  CAF-ZT for, 293
  chemotherapy for, 292
  CMF for, 292
  DCIS in, 295
  ECOG on, 293
  goserelin for, 361
  invasive cancer in, 295
  OA in, 140–141
  oophorectomy with tamoxifen for, 294
  psychosocial variables in, 297
  QOL in, 361–362
  tamoxifen for, 141, 293–294
Primary care physician (PCP), 346–347
Primary systemic therapy (PST), 103–116, 261

duration of, 261
Her2/neu and, 257
pCR and, 257
SLN biopsy and, 257
PRIME, see Postoperative Radiotherapy In Minimum-risk Elderly
PROACT, 111
Progesterone receptors (Pr, PgR), 38, 77, 139
clodronate and, 164
IHC for, 49, 50–51
pCR and, 106
as predictive factor, 17
pregnancy and, 317
Prognostic and predictive factors, 13–26
Progression free survival (PFS), 142, 250
with anthracyclines, 264
with lapatinib, 204
Proportional hazards (PH), 78
PROs, see Patient reported outcomes
Proteomics, 33–35
Provisional Clinical Opinions (PCOs), 74
PST, see Primary systemic therapy
Psychosocial variables, 222, 225–228, 342–343
cognitive function and, 408
in premenopausal women, 297
PTEN, see Plasma phosphatase and tensin
Pulmonary toxicity, with adjuvant chemotherapy, 131
PWB, see Physical Well Being
Pyrophosphate, 163

Q
QOL, see Quality of life
Quality of life (QOL), 130, 343
with adjuvant chemotherapy, 131–132
with adjuvant endocrine therapy, 353–363
AIs and, 355
with anastrozole, 358
ATAC on, 357
in BCIRG, 184
chemotherapy and, 388
for elderly patients, 304
male breast cancer and, 463
MENQOL, 354
with letrozole, 359
for premenopausal women, 361–362
surveillance tests and, 338–339
with tamoxifen, 150, 358

R
Radical mastectomy, 4
Radiotherapy (RT)
AIs and, 259
chemotherapy with, 283
with CMF, 258, 282, 283
delay of, 282–283
for elderly patients, 305–306
local complications with, 339
mastectomy and, 282
recurrence with, 284
sequencing with, 283–287
with tamoxifen, 259, 284
timing of, 258–259
RCB, see Residual cancer burden
Real time reverse transcription polymerase chain reaction (RT-PCR), 10, 20, 113
RECIST, 202
Recurrence
with anthracyclines, 8, 123
CMF and, 361
CRA and, 367
detection of, 333–339
goserelin and, 361
with letrozole, 152
lymph nodes and, 141
pregnancy and, 379
in premenopausal women, 292
with RT, 284
symptoms of, 335
TTDR
for anastrozole, 306
in HERA, 184
in NSABP, 184
with trastuzumab, 188
TTR, 147
tumor size and, 141
Recurrence score (RS), 113
Referral pathways, 221
Relapse-free survival (RFS), 110, 142, 149
with FinHER, 189
with trastuzumab, 190
Relapse rate (RR), 142
Renal blood flow, during pregnancy, 319
Residual cancer burden (RCB), 114
Retinoblastoma, 379
RFS, see Relapse-free survival
RNA, 32, 33–34
for microarray-based expression profiling, 55
Royal Marsden, 106, 107
RR, see Relapse rate
RS, see Recurrence score
RT, see Radiotherapy
RT-PCR, see Real time reverse transcription polymerase chain reaction

S
SABCS, see San Antonio Cancer Symposums
San Antonio Cancer Symposums (SABCS), 64, 69
on lapatinib, 202
Satariano Index, 301
Scandinavian Breast Caner Study Group, 249
Scottish Cancer Trials Breast Group, 8, 141
Scottish/Imperial Cancer Research Fund, 144, 145
SCT, see Stem cell transplant
SEER, see Surveillance Epidemiology and End Results
SELDI-TOF, see Surface-enhanced laser desorption and ionization with time of flight spectrometry
Selective estrogen receptor destroyer (SERD), 139
Selective estrogen receptor modulators (SERMs), 139, 261, 354
timing of, 267–269
Selective use of postoperative radiotherapy after mastectomy (SUPREMO), 282
Self-disclosure, 442–445
Self esteem, 229
Sentinel lymph nodes (SLN) biopsy of lymphedema and, 339
PST and, 257
dissection of, 45–46
IHC for, 43
SERD, see Selective estrogen receptor destroyer
SERMs, see Selective estrogen receptor modulators
5HT3-serotonin antagonists, 322, 430
Serum creatinine, 174
Sexual function, 342, 345, 357, 360 with adjuvant chemotherapy, 131 tamoxifen and, 340–341
Side effects of chemotherapy, 339–342 of endocrine therapy, 362
of lapatinib, 203 patient vs. clinician reporting of, 362 of tamoxifen, 6
See also Toxicity
Single agent phenylalanine mustard (L-PAM), 7
Single nucleotide polymorphisms, 193
Single sample predictions (SSP), 16
SK BR-3, 38
Skipper Schabel model, 239–240
Sleep, 357, 360
Sliding-window approach, 81
SLN, see Sentinel lymph nodes
Slow freeze-thaw, 378
Social support, 227
Social Well Being (SWB), 356, 358
SOFT, see Suppression of Ovarian Function Trial
SOLE, 270
Solid tumors, 44
Southwest Oncology Group (SWOG), 113 on clodronate, 164
on goserelin, 296, 375
on premenopausal women, 292
Sphingosine-1-phosphate, 375
SSP, see Single sample predictions
St. Gallen Consensus’s Panel, 23, 132
Staging, 44–46
axillary lymph nodes and, 45
costs and, 432–433
tumor size and, 47
Statistics, 77–88
Stem cell transplant (SCT), 67
with chemotherapy, 248–251
STEPP, see Subpopulation Treatment Effect Pattern Plots
Stress, see Distress
Stroke, 405
tamoxifen and, 342
Subgroup controversy, 78–79
Subpopulation Treatment Effect Pattern Plots (STEPP), 77, 81
DFS and, 83, 84, 85
ER and, 83
Kaplan-Meier method and, 83
Substance abuse, 227
Suicide, 226
Supportive care, 219–233
age and, 227
costs of, 430–431
endocrine therapy as, costs of, 431
during pregnancy, 322
Suppression of Ovarian Function Trial (SOFT), 150
on ovarian suppression, 368
on premenopausal women, 294
SUPREMO, see Selective use of postoperative radiotherapy after mastectomy
Surface-enhanced laser desorption and ionization with time of flight spectrometry (SELDI-TOF), 34
Surgery
for elderly patients, 304–305
vs. endocrine therapy, for elderly patients, 304
local complications with, 339
specimens in, 42–43
timing of, 256
Surveillance Epidemiology and End Results (SEER), 255, 299, 423
on RT delay, 283
Survivorship issues, 231–232
SWB, see Social Well Being
Swedish Breast Cancer group, 17
SWOG, see Southwest Oncology Group

T
TABLE, see Takeda Adjuvant Breast Cancer Study with Leuprolrelin Acetate
TAC, see Docetaxel, doxorubicin, cyclophosphamide
TAILOR x, see Trial Assigning IndividuaLized Options for Treatment (Rx)
Takeda Adjuvant Breast Cancer Study with Leuprolrelin Acetate (TABLE), 144, 145
Tamoxifen, 5, 150, 354
AIs and, 151–155, 171, 269
aminoglutethimide and, 155
anastrozole and, 111, 155, 306
anthracyclines and, 262
bel-2 and, 19
bisphosphonates and, 170–171
BMD and, 341
CAF with, 22
in CAF-ZT, 147
for premenopausal women, 293
with chemotherapy, 113, 141–143
cholesterol and, 342
CMF and, 262
cognitive function and, 394, 404
cost of, 429–430
cyclophosphamide and, 7
deep venous thrombosis and, 342
DFS with, 141
in doxorubicin, cyclophosphamide, tamoxifen, 33
doxorubicin and, 7
duration of treatment with, 6
EBCTCG and, 67
for elderly patients, 309
endometrial cancer and, 341
epirubicin and, 112
for ER positive, 20, 67, 139
exemestane and, 269
fluorouracil and, 262
goserelin and, 170
gynecologic function and, 340–341
HER2/neu and, 17, 19
letrozole and, 111, 153
LHRH and, 170
triptorelin and, 148
melphalan and, 262
myocardial infarction and, 342
OA and, 143
OA with, 148–149
FAC and, 149
oophorectomy and, 294
osteoporosis and, 170
ovarian suppression with, 141
in PAFT, 123
postmenopausal women and, 269–270
during pregnancy, 321
for premenopausal women, 141, 293–294
QOL with, 150, 358
RT with, 258–259, 284
side effects of, 6
stroke and, 342
thromboembolic events and, 342
timing of, 267–269
Tamoxifen and Exemestane Adjuvant Multicenter (TEAM), 151–152, 307
Tamoxifen and Exemestane Trial (TEXT), 150
on premenopausal women, 294
TanGo, 129
Targeted therapies, 271–272
costs of, 431–432
TAT, see Thrombin-anti-thrombin complex
TAU protein
epirubicin and, 25
paclitaxel and, 25
Taxanes, 7, 69, 121
  in adjuvant chemotherapy, 126
  DFS with, 246
dose intensity of, 243
dose scheduling for, 245
  for elderly patients, 310
  for p-53, 24
  pCR and, 107–110
  predictive markers for, 24–25
during pregnancy, 320
Taxotere, with anthracyclines, 109
TCH, see Docetaxel, carboplatin, trastuzumab
TEACH, see Tykerb Evaluation After Chemotherapy
TEAM, see Tamoxifen and Exemestane Adjuvant Multicenter
Telomerase, 406
TEXT, see Tamoxifen and Exemestane Trial
TGF-α, 200
Thiotepa, 249
  in CTC, 249, 393
  See also Cyclophosphamide, thiotepa, carboplatin
Thrombin-anti-thrombin complex (TAT), 405
Thromboembolic events, 151–152, 262, 405
tamoxifen and, 342
Time to distant recurrence (TTDR)
  for anastrozole, 306
  in HERA, 184
  in NSABP, 184
  with trastuzumab, 188
Time to recurrence (TTR), 147
Timing of adjuvant therapy, 255–272
Tissue banks, 43–44
Tissue lysate arrays (TLA), 34
TKI, see Tyrosine kinase inhibitors
TLA, see Tissue lysate arrays
TNF-α, see Tumor necrosis factor alpha
TNM, 45
TOI, see Trial Outcome Index
Topo II α, see Topoisomerase II alpha
Topoisomerase II alpha (Topo IIα)
  IHC for, 24
  inhibitors of, 122
  as predictive factor, 22–24
  trastuzumab and, 193
Topotecan, 320
Total body water, during pregnancy, 319
Toxicity
  with adjuvant chemotherapy, 130
dose intensity and, 242
  pulmonary, 131
  See also Cardiac toxicity
TransATAC study, 19
Transcriptomics, 32–33
Trastuzumab (Herceptin), 25, 52, 181–193, 354
AC and, 181
  bevacizumab and, 205
  cardiac toxicity with, 130, 185–186, 188
  with chemotherapy, for HER2, 114
  CHF with, 182, 186
  costs of, 431–432
  DFS with, 182, 186–187, 271
  ErbB2 and, 284
  HER-2 and, 77, 181–182, 191, 271
  HER2/neu and, 9
  HR with, 192–193
  interstitial pneumonitis with, 189
  lapatinib and, 115, 201–202, 204–206, 210
  LVEF and, 186
  for MBC, 181
  metabolomics and, 193
  optimal duration of, 191
  ovarian suppression with, 182, 188
  p95 and, 203
  during pregnancy, 321
  PTEN and, 193, 200
  resistance to, 198–200
  RFS with, 190
  in TCH, 187
  Topo IIα and, 193
  TTDR with, 188
Trial Assigning IndividuaLized Options for Treatment (Rx) (TAILOR x), 77, 85–88, 149
Trial Outcome Index (TOI), 356
Triptorelin, tamoxifen with LHRH and, 148
Troponins, 193
TTDR, see Time to distant recurrence
TTR, see Time to recurrence
Tubule formation, 48
Tumor grade, 44, 48–49
  mammography and, 45
  as prognostic factor, 15
Tumor markers, 337–338
Tumor necrosis factor alpha (TNF-α), 406
Tumor size
  CNB and, 47
  as prognostic factor, 14
  recurrence and, 141
  staging and, 47
Tumor specific antibodies, 37
Tykerb, see Lapatinib
Tykerb Evaluation After Chemotherapy (TEACH), 209
Tyrosine kinase inhibitors (TKI), 115, 197–198
for HER2, 129
lapatinib and, 205–206
See also specific drugs

U
Ultrasound, 336
Universal Declaration of Human Rights, 453
uPA, see Urokinase-type plasminogen activator
UPA/PAI-1
ELISA for, 16
as prognostic factor, 15–16
Urokinase-type plasminogen activator (uPA), 260
US Preventive Services Task Force, 335

V
Vaginal bleeding, 357, 360
anastrozole and, 306
from tamoxifen, 150–151
Vaginal discharge, 357, 360
from tamoxifen, 150–151, 340–341
Vascular dementia, 406
Vascular endothelial cell growth factor (VEGF), HER2/neu and, 205
VEGF, see Vascular endothelial cell growth factor
VEGFR, 115, 205
Vinca-alkaloids, 320
Vincristine
in AVCF, 123
CMF and, 123
in CVAP, 108, 109
Vinorelbine
docetaxel and, 189
for elderly patients, 310
Vinorelbine, capecitabine (NX), 107
Vitamin D, 174, 341
Vomiting, 357, 360

W
Warfarin, 407
WBI, see Whole-breast irradiation
Weight gain, 229, 357, 360
lymphedema and, 339
West German Study Group, 249
Whole-breast irradiation (WBI), 258
Women’s Health Initiative, 403–404

X
Xenotransplantation, 378

Y
Y-ME, 464
Young patients, see Premenopausal women

Z
ZEBRA, see Zoladex Early Breast Cancer Research Association
ZIPP, see Zoladex in Premenopausal Patients
Zoladex Early Breast Cancer Research Association (ZEBRA), 144, 145
on CMF, 361
on goserelin, 361
Zoladex in Premenopausal Patients (ZIPP), 145, 147
Zoledronate, 150
Zoledronic acid
BMD and, 169
clodronate and, 164
osteoporosis and, 170, 173